Sean Dolan

3.9k total citations · 2 hit papers
38 papers, 1.6k citations indexed

About

Sean Dolan is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Sean Dolan has authored 38 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 13 papers in Genetics and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Sean Dolan's work include Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Sean Dolan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Sean Dolan collaborates with scholars based in Canada, United Kingdom and United States. Sean Dolan's co-authors include David R. Anderson, Michael J. Kovacs, Marc Rodger, Michael Gent, William Geerts, Mark Crowther, Susan Solymoss, Jim A. Julian, Jeffrey S. Ginsberg and Clive Kearon and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Sean Dolan

35 papers receiving 1.6k citations

Hit Papers

Comparison of Low-Intensity Warfarin Therapy with Convent... 2003 2026 2010 2018 2003 2020 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
    2003 544 citations Clive Kearon, Jeffrey S. Ginsberg et al. New England Journal of Medicine profile →
  2. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    2020 252 citations Paolo Ghia, Andrzej Pluta et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sean Dolan Canada 15 788 663 595 430 311 38 1.6k
Laura Russo Italy 22 652 0.8× 575 0.9× 350 0.6× 464 1.1× 74 0.2× 56 1.7k
Kristen M. Sanfilippo United States 19 477 0.6× 395 0.6× 288 0.5× 186 0.4× 157 0.5× 101 1.2k
Eduardo Rocha Spain 27 688 0.9× 757 1.1× 584 1.0× 143 0.3× 177 0.6× 108 2.0k
Tzu‐Fei Wang Canada 22 1.9k 2.4× 494 0.7× 1.5k 2.4× 197 0.5× 105 0.3× 111 2.6k
Hans‐Martin Otten Netherlands 13 595 0.8× 324 0.5× 348 0.6× 308 0.7× 51 0.2× 28 1.1k
Gregory C. Connolly United States 21 1.2k 1.6× 269 0.4× 687 1.2× 88 0.2× 138 0.4× 31 1.8k
Jeannine Kassis Canada 25 1.5k 2.0× 756 1.1× 868 1.5× 144 0.3× 95 0.3× 64 2.6k
L. Heilmann Germany 21 576 0.7× 422 0.6× 437 0.7× 138 0.3× 50 0.2× 97 1.5k
Avi Leader Israel 20 321 0.4× 336 0.5× 357 0.6× 167 0.4× 87 0.3× 89 1.2k
Annelise Segers United States 16 2.0k 2.5× 686 1.0× 1.9k 3.3× 564 1.3× 41 0.1× 31 2.8k

Countries citing papers authored by Sean Dolan

Since Specialization
Citations

This map shows the geographic impact of Sean Dolan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sean Dolan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sean Dolan more than expected).

Fields of papers citing papers by Sean Dolan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sean Dolan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sean Dolan. The network helps show where Sean Dolan may publish in the future.

Co-authorship network of co-authors of Sean Dolan

This figure shows the co-authorship network connecting the top 25 collaborators of Sean Dolan. A scholar is included among the top collaborators of Sean Dolan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sean Dolan. Sean Dolan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dolan, Sean, et al.. (2023). Restorative dentistry clinical decision-making for hypodontia: peg and missing lateral incisor teeth. BDJ. 235(7). 471–476. 6 indexed citations
2.
Dolan, Sean, et al.. (2023). Apical periodontitis and autoimmune diseases—should we be screening patients prior to therapy?. Evidence-Based Dentistry. 24(2). 64–65. 1 indexed citations
3.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2022). Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. HemaSphere. 6(12). e801–e801. 65 indexed citations
4.
Ghia, Paolo, Małgorzata Wach, Daniel Lysák, et al.. (2022). P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP. HemaSphere. 6. 566–567. 1 indexed citations
5.
Jurczak, Wojciech, Andrzej Pluta, Małgorzata Wach, et al.. (2021). Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 393–393. 15 indexed citations
6.
Venner, Christopher P., Richard LeBlanc, Irwindeep Sandhu, et al.. (2021). Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN‐003/MYX.1 single arm phase II trial. American Journal of Hematology. 96(5). 552–560. 12 indexed citations
7.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 38(25). 2849–2861. 252 indexed citations breakdown →
8.
Dolan, Sean, Anna Christofides, Sarah Doucette, & Mona Shafey. (2020). Highlights from ASCO 2020: Updates on the Treatment of Chronic Lymphocytic Leukemia. Current Oncology. 27(4). 420–432. 5 indexed citations
9.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results. Clinical Lymphoma Myeloma & Leukemia. 20. S220–S221. 1 indexed citations
10.
11.
Dolan, Sean, et al.. (2017). Functional and patient-reported outcomes of the Swanson metacarpo-phalangeal arthroplasty in the rheumatoid hand. Archives of Orthopaedic and Trauma Surgery. 137(5). 725–731. 7 indexed citations
12.
Chanan‐Khan, Asher, Miklós Egyed, Tadeusz Robak, et al.. (2017). Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). Leukemia. 31(5). 1240–1243. 21 indexed citations
13.
Riches, Philip L., et al.. (2016). Patient rated outcomes study into the surgical interventions available for the rheumatoid hand and wrist. Archives of Orthopaedic and Trauma Surgery. 136(4). 563–570. 15 indexed citations
14.
Dolan, Sean, et al.. (2016). Management of Labour and Delivery in a Patient With Acquired Factor VII Deficiency With Inhibitor: A Case Report. Journal of Obstetrics and Gynaecology Canada. 38(2). 160–163. 3 indexed citations
15.
Dolan, Sean, et al.. (2009). Supporting Online Learners: Blending High-Tech with High-Touch.. 2 indexed citations
16.
Kearon, Clive, Jim A. Julian, Michael J. Kovacs, et al.. (2008). Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood. 112(12). 4432–4436. 81 indexed citations
17.
Shustik, Chaim, Andrew R. Belch, Sue Robinson, et al.. (2006). A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. British Journal of Haematology. 136(2). 203–211. 58 indexed citations
18.
Couban, Stephen, Michael Goodyear, Margot J. Burnell, et al.. (2005). Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous Catheter–Associated Thrombosis in Patients With Cancer. Journal of Clinical Oncology. 23(18). 4063–4069. 243 indexed citations
19.
Kearon, Clive, Jeffrey S. Ginsberg, Michael J. Kovacs, et al.. (2003). Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine. 349(7). 631–639. 544 indexed citations breakdown →
20.
Quirt, Ian, Michael J. Kovacs, Susan Burdette-Radoux, et al.. (2002). Epoetin alfa in patients not on chemotherapy [ndash ] Canadian data. Seminars in Oncology. 29(3 Suppl 8). 75–80. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Russo Breakdown of academic impact, for papers by Kristen M. Sanfilippo Breakdown of academic impact, for papers by Eduardo Rocha Breakdown of academic impact, for papers by Tzu‐Fei Wang Breakdown of academic impact, for papers by Hans‐Martin Otten Breakdown of academic impact, for papers by Gregory C. Connolly Breakdown of academic impact, for papers by Jeannine Kassis Breakdown of academic impact, for papers by L. Heilmann Breakdown of academic impact, for papers by Avi Leader Breakdown of academic impact, for papers by Annelise Segers
Rankless by CCL
2026